Each tablet contains: Glimepiride 6 mg.

30.00 EGP

Purchase this product now and earn 30 Points!

DOLCYL 6MG 30TAB; glimepiride, blood glucose regulators .


Each tablet contains: Glimepiride 6 mg.


Dolcyl is indicated for the treatment of type 2 diabetes mellitus , when diet, physical exercise and weight reduction alone are not adequate.


Follow all directions given to you by your pharmacist or doctor carefully . They may differ from the information contained in this leaflet

Ask your pharmacist or doctor for help if you do not understand the instructions on the box .

The recommended dose is : –

For oral administration: The basis for successful treatment of diabetes is a good diet, regular physical activity, as well as routine checks of blood and urine. Tablets or insulin cannot compensate if the patient does not keep to the recommended diet. Dosage is determined by the results of blood and urinary glucose determenations. The starting dose is 1 mg glimepiride per day. If good control is achieved this dosage should be used for maintenance therapy. For the different dosage regimens appropriate strengths are available. If control is unsatisfactory, the dosage should be increased, based on the glycaemic control, in a stepwise manner with an interval of about 1 to 2 weeks between each step, to 2, 3 or 4 mg glimepiride per day. A dosage of more than 4 mg glimepiride per day gives better results only in exceptional cases. The maximum recommended dose is 6 mg glimepiride per day. In patients not adequately controlled with the maximum daily dose of metformin, concomitant glimepiride therapy can be initiated. While maintaining the metformin dose, the glimepiride therapy is started with a low dose, and is then titrated up depending on the desired level of metabolic control up to the maximum daily dose . The combination therapy should be initiated under close medical supervision. In patients not adequately controlled with the maximum daily dose of Dolcyl, concomitant insulin therapy can be initiated if necessary. While maintaining the glimepiride dose, insulin treatment is started at low dose and titrated up depending on the desired level of metabolic control. The combination therapy should be initiated under close medical supervision. Normally a single daily dose of glimepiride is sufficient. It is recommended that this dose be taken shortly before or during a substantial breakfast or – if none is taken- shortly before or during the first main meal. If a dose is forgotten, theis should not be corrected by increasing the next dose. Tablets should be swallowed whole with some liquid. If a patient has a hypoglycaemic reaction on 1 mg glimepiride daily, this indicates that they can be controlled by diet alone. In the course of treatment, as an improvement in control of diabetes is associated with higher insulin sensitivity, glimepiride requirements may fall. To avoid hypoglycaemia timely dose reduction or cessation of therapy must therefore be considered. Change in dosage may also be necessary, if there are changes in weight or life style of the patient, or other factors that increase the risk of hypo- or hyperglycaemia. Switch over from other oral hypoglycaemic agents of Dolcyl A switch over from other oral hypoglyceamic agents ro Dolcyl can generally be done. For the switch over to Dolcyl the strength and the half-life of the previous medicinal product has to be taken into account. In some cases, especially in antidiabetics with a long half-life ( e.g. chloropropamide ), a wash out period of a few days is advisable in order to minimise the risk of hypoglycaemic reactions due to the additive effect. The recommended starting dose is 1 mg glimepiride per day. Based on the response the glimepiride dosage may be increased stepwise, as indicated earlier. Switch over from insulin to Dolcyl in exceptional cases, where type 2 diabeteic patients are regulatedon insulin, a changover to Dolcyl may be indicated. The changeover should be undertaken under close medical supervision. Special Populations: Children and adolescents: There are no data available on the use of glimepiride in patients under 8 years of age . For Children aged 8 to 17 years, there are limited data on glimepiride as monotherapy.The available data on safety and efficacy are insufficient in the paediatric population and therefore such use is not recommended.


After ingestion of an overdose hypoglycaemia may occur, lasting from 12 to 72 hours, and may recur after an initial recovery. Symptoms may not be present for up to 24 hours after ingestion, In general observation in hospital is recommended. Nausea, vomiting and epigastricpain may occur, The hypoglycaemia may in general be accompained by neurological symptoms like restlessness, tremor, visual disturbances, co-ordination problems, sleepiness, coma and convulsions. Treatment primarily consists of preventing absorption by inducing vomiting and then drinking water or lemonade with activated charcoal (adsorbent) and sodium-sulphate (laxative). If large quantities have been ingested, gastric lavage is indicated, followed by activated charcoal and sodium-sulphate. In case of (severe) overdosage hospitalisation in an intensive care department is indicated. Start the administration of glucose as soon as possible, if necessary by a bolus intravenous injection of 50 ml of a 50% solution, followed by an infusion of a 10 % solution with strict monitoring of blood glucose . Further treatment should be symptomatic. In particular when treating hypoglycaemia due to accidental intake of Dolcyl in infants and young children , the dose of glucose given must be carefully controlled to avoid the possibility of producing dangerous hyperglycaemia. Blood glucose should be closely monitored.


Glimepiride is contraindicated in patients with the following conditions : hypersensitivity to Glimepiride , other sulfonylureas or sulfonamides or to any of the excipients. insulin dependent diabetes. Diabetic coma. Ketoacidosis, Sever renal or hepatic function disorders. In case of severe renal or hepatic function disorders, a change over to insulin is required.


Store at a temperature not exceeding 25 °C in dry place.
Carton box containing 3 ( Al/PVC) strips, each of 10 tablets + inner leaflet.
Medical Union Pharmaceuticals, Abu-Sultan,Ismailia, Egypt.



How to use


There are no reviews yet.

Show reviews in all languages (1)

Be the first to review “DOLCYL 6MG 30TAB”

Your email address will not be published.

Shopping Cart
Don`t copy text!
Scroll to Top